PDCD1 and biliary tract neoplasm: These findings underscore the potential of targeting immune checkpoints, particularly PD-1/PD-L1, as a therapeutic strategy for biliary tract cancer, providing a foundation for ongoing clinical trials to evaluate their efficacy and safety.